Ovarian mucinous adenocarcinoma

Summary

Ovarian mucinous adenocarcinoma (MONDO:0005601) is a disease with 4 cohort genes (22 GWAS associations across 3 studies) and 22 clinical trials. Top therapeutic interventions include paclitaxel, bevacizumab, and topotecan hydrochloride.

At a glance

• Prevalence: 1-9 / 1 000 000 (Europe) [Orphanet-validated]
• Cohort genes: 4
• GWAS associations: 22
• Clinical trials: 22

Clinical features

Epidemiology

Prevalence records

24 prevalence record(s), Orphanet, top 20 (validated / broadest geography first):

Type	Class	Value	Geography	Validation
Annual incidence	1-9 / 1 000 000	0.85	Europe	Validated
Annual incidence	1-9 / 1 000 000	0.497	Austria	Validated
Annual incidence	1-9 / 1 000 000	0.883	Belgium	Validated
Annual incidence	1-9 / 1 000 000	0.815	Croatia	Validated
Annual incidence	1-9 / 1 000 000	0.995	Czech Republic	Validated
Annual incidence	1-9 / 1 000 000	0.666	Germany	Validated
Annual incidence	1-9 / 1 000 000	0.469	Iceland	Validated
Annual incidence	1-9 / 1 000 000	0.706	Ireland	Validated
Annual incidence	1-9 / 1 000 000	0.666	Italy	Validated
Annual incidence	1-9 / 1 000 000	0.503	Latvia	Validated
Annual incidence	1-9 / 1 000 000	0.567	Lithuania	Validated
Annual incidence	1-9 / 1 000 000	0.717	Norway	Validated
Annual incidence	1-9 / 1 000 000	0.665	Poland	Validated
Annual incidence	1-9 / 1 000 000	0.49	Portugal	Validated
Annual incidence	1-9 / 1 000 000	0.945	Slovakia	Validated
Annual incidence	1-9 / 1 000 000	0.601	Slovenia	Validated
Annual incidence	1-9 / 1 000 000	0.695	Spain	Validated
Annual incidence	1-9 / 1 000 000	0.563	Switzerland	Validated
Annual incidence	1-9 / 1 000 000	0.76	Netherlands	Validated
Annual incidence	1-9 / 1 000 000	0.815	United Kingdom	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	ovarian mucinous adenocarcinoma
Mondo ID	MONDO:0005601
EFO	EFO:0006462
Orphanet	398961
DOID	DOID:3606
ICD-11	869438441
NCIT	C5243
UMLS	C1335167
MedGen	235418
GARD	0021651
Anatomy (UBERON)	UBERON:0000992
Is cancer (heuristic)	no

Also known as: mucinous adenocarcinoma of ovary · mucinous adenocarcinoma of the ovary · mucinous carcinoma of ovary · mucinous carcinoma of the ovary · ovarian mucinous adenocarcinoma · ovarian mucinous carcinoma · ovary mucinous adenocarcinoma

Data availability: 22 GWAS associations (3 studies) · 32 cell lines.

Disease family

An umbrella term covering 1 Mondo subtype.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › adenocarcinoma › ovarian adenocarcinoma › ovarian mucinous adenocarcinoma

Related subtypes (6): ovarian cystadenocarcinoma, rete ovarii adenocarcinoma, Krukenberg carcinoma, ovarian serous adenocarcinoma, ovarian clear cell adenocarcinoma, ovarian endometrioid adenocarcinoma

Subtypes (1): ovarian mucinous cystadenocarcinoma

Genetics & variants

GWAS landscape

22 GWAS associations across 3 studies. Top hits map to 10 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
chr19:39738787	9e-28		T	0.69
rs688187	1e-22	IFNL3P1 - IFNL3	A	1.43
chr2:177037311	9e-16		G	0.24
chr3:138849543	8e-15		C	1.29
rs711830	1e-14	HOXD3, HAGLR	A	1.27
rs6755777	1e-13	HAGLROS, HAGLR	T	1.26
rs112071820	2e-13	MRPS22	GCCAG	1.29
rs752590	2e-12	PAX8-AS1	G	1.3
chr2:113979364	5e-12		A	1.31
rs320203	2e-08	ARL2BPP7 - RNU6-329P	A	1.29
rs72827480	3e-08	INHBB - LINC01101	C	0.85
chr9:104943226	1e-07		A	0.23
rs72831838	8e-07	PAX8-AS1, PAX8	?	1.39
rs11651755	2e-06	HNF1B	T	1.15
chr17:36099840	6e-06		T	0.13
rs6470494	6e-06	CASC19, PCAT1	C	0.87
rs2594950	7e-06	LINC01117	C	0.87

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90244172	Dareng EO	2024	2,587	105,724	Integrative multi-omics analyses to identify the genetic and functional mechanisms underlying ovarian cancer risk regions.
GCST004419	Phelan CM	2017	2,566	40,941	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.
GCST002967	Kelemen LE	2015	1,003	21,693	Genome-wide significant risk associations for mucinous ovarian carcinoma.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	1
Tier 3: regulatory	0
Tier 4: intronic/intergenic	16

MAF distribution

Bucket	Variants
common (>=0.05)	17
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	0

Functional consequences

Consequence	Count
intron_variant	8
unknown	6
3_prime_UTR_variant	1
non_coding_transcript_exon_variant	1
intergenic_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
chr19:39738787				0.307			9e-28	Tier 4: intronic/intergenic
rs688187	19	39242112	G>A	0.313	intron_variant	IFNL3P1 - IFNL3	1e-22	Tier 4: intronic/intergenic
chr2:177037311				0.32			9e-16	Tier 4: intronic/intergenic
chr3:138849543				0.288			8e-15	Tier 4: intronic/intergenic
rs711830	2	176172583	A>C,G,T	0.319	3_prime_UTR_variant	HOXD3, HAGLR	1e-14	Tier 2: splice/UTR
rs6755777	2	176178498	T>A,G	0.319	non_coding_transcript_exon_variant	HAGLROS, HAGLR	1e-13	Tier 4: intronic/intergenic
rs112071820	3	139130269	G>GCCACATTCAGAAT,GCCAGATTCAGAAT	0.283	intron_variant	MRPS22	2e-13	Tier 4: intronic/intergenic
rs752590	2	113215368	A>G	0.211	intron_variant	PAX8-AS1	2e-12	Tier 4: intronic/intergenic
chr2:113979364				0.15			5e-12	Tier 4: intronic/intergenic
rs320203	9	102180944	C>A	0.15	intron_variant	ARL2BPP7 - RNU6-329P	2e-08	Tier 4: intronic/intergenic
rs72827480	2	120388925	T>A,C,G	0.36	intergenic_variant	INHBB - LINC01101	3e-08	Tier 4: intronic/intergenic
chr9:104943226				0.146			1e-07	Tier 4: intronic/intergenic
rs72831838	2	113258824	C>G,T	0.14	intron_variant	PAX8-AS1, PAX8	8e-07	Tier 4: intronic/intergenic
rs11651755	17	37739849	T>C	0.486	intron_variant	HNF1B	2e-06	Tier 4: intronic/intergenic
chr17:36099840				0.484			6e-06	Tier 4: intronic/intergenic
rs6470494	8	127075659	T>A,C,G	0.31	intron_variant	CASC19, PCAT1	6e-06	Tier 4: intronic/intergenic
rs2594950	2	176643894	G>C	0.31	intron_variant	LINC01117	7e-06	Tier 4: intronic/intergenic

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 4 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
PAX8	Orphanet:146	Differentiated thyroid carcinoma
PAX8	Orphanet:95712	Thyroid ectopia
PAX8	Orphanet:95713	Athyreosis
PAX8	Orphanet:95720	Thyroid hypoplasia

Cohort genes → proteins

4 cohort genes, 4 distinct canonical proteins.

Evidence partition

Subset	Genes
gwas_only	4

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
IFNL3	HGNC:18365	ENSG00000197110	Q8IZI9	Interferon lambda-3	gwas
IFNL4	HGNC:44480	ENSG00000272395	K9M1U5	Interferon lambda-4	gwas
HOXD3	HGNC:5137	ENSG00000128652	P31249	Homeobox protein Hox-D3	gwas
PAX8	HGNC:8622	ENSG00000125618	Q06710	Paired box protein Pax-8	gwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
IFNL3	Interferon lambda-3	Cytokine with antiviral, antitumour and immunomodulatory activities.
IFNL4	Interferon lambda-4	Cytokine that may trigger an antiviral response activating the JAK-STAT pathway and up-regulating specifically some interferon-stimulated genes.
HOXD3	Homeobox protein Hox-D3	Sequence-specific transcription factor which is part of a developmental regulatory system that provides cells with specific positional identities on the anterior-posterior axis.
PAX8	Paired box protein Pax-8	Transcription factor for the thyroid-specific expression of the genes exclusively expressed in the thyroid cell type, maintaining the functional differentiation of such cells.

Protein-family classification

Druggable: 0 · Difficult: 2 · Unknown: 2 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Transcription factor	2	4.1×	0.149
Other/Unknown	2	0.9×	0.769

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
IFNL3	Other/Unknown	no		INF_lambda, IFN-lambda_sf
IFNL4	Other/Unknown	no		INF_lambda, IFN-lambda_sf
HOXD3	Transcription factor	no		HD, Homeobox_Antennapedia_CS, Homeodomain-like_sf
PAX8	Transcription factor	no		Paired_dom, Homeodomain-like_sf, Pax2_C

Expression context

Cohort genes with no expression data: 0.

2 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	2
broad (>20)	2
unknown	0

Top tissues across cohort

Tissue	Cohort genes
male germ line stem cell (sensu Vertebrata) in testis	2
primordial germ cell in gonad	2
granulocyte	1
prefrontal cortex	1
corpus epididymis	1
germinal epithelium of ovary	1
right uterine tube	1
left lobe of thyroid gland	1
right lobe of thyroid gland	1
thyroid gland	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
IFNL3	15		yes	male germ line stem cell (sensu Vertebrata) in testis, primordial germ cell in gonad, granulocyte
IFNL4	18		yes	male germ line stem cell (sensu Vertebrata) in testis, primordial germ cell in gonad, prefrontal cortex
HOXD3	169	broad	marker	corpus epididymis, germinal epithelium of ovary, right uterine tube
PAX8	242	ubiquitous	marker	right lobe of thyroid gland, left lobe of thyroid gland, thyroid gland

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
PAX8	1,994
HOXD3	933
IFNL3	810
IFNL4	1

Structural data

PDB: 3 · AlphaFold-only: 1 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
IFNL3	Q8IZI9	3
IFNL4	K9M1U5	1
PAX8	Q06710	1

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
HOXD3	P31249	58.01

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 4. Enrichment computed across 4 evidence-associated genes (3 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Formation of intermediate mesoderm	1	475.8×	0.008	PAX8
Formation of the nephric duct	1	211.5×	0.009	PAX8
Interleukin-20 family signaling	1	141.0×	0.009	IFNL3
Activation of anterior HOX genes in hindbrain development during early embryogenesis	1	30.4×	0.032	HOXD3

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 4 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
type III interferon-mediated signaling pathway	2	766.0×	1e-04	IFNL3, IFNL4
thyroid gland development	2	271.8×	4e-04	HOXD3, PAX8
positive regulation of immune response	2	240.7×	4e-04	IFNL3, IFNL4
DNA-templated transcription	2	112.3×	0.002	HOXD3, PAX8
cellular response to virus	2	100.3×	0.002	IFNL3, IFNL4
regulation of thyroid-stimulating hormone secretion	1	4213.0×	0.002	PAX8
pronephric field specification	1	2106.5×	0.002	PAX8
metanephric comma-shaped body morphogenesis	1	2106.5×	0.002	PAX8
obsolete negative regulation of mesenchymal cell apoptotic process involved in metanephric nephron morphogenesis	1	2106.5×	0.002	PAX8
obsolete negative regulation of apoptotic process involved in metanephric collecting duct development	1	2106.5×	0.002	PAX8
obsolete negative regulation of apoptotic process involved in metanephric nephron tubule development	1	2106.5×	0.002	PAX8
positive regulation of metanephric DCT cell differentiation	1	2106.5×	0.002	PAX8
negative regulation of mesenchymal cell apoptotic process involved in metanephros development	1	1404.3×	0.003	PAX8
glossopharyngeal nerve morphogenesis	1	1053.2×	0.003	HOXD3
metanephric distal convoluted tubule development	1	1053.2×	0.003	PAX8
metanephric S-shaped body morphogenesis	1	1053.2×	0.003	PAX8
positive regulation of thyroid hormone generation	1	1053.2×	0.003	PAX8
metanephric epithelium development	1	842.6×	0.003	PAX8
metanephric nephron tubule formation	1	842.6×	0.003	PAX8
regulation of metanephric nephron tubule epithelial cell differentiation	1	842.6×	0.003	PAX8
tyrosine phosphorylation of STAT protein	1	702.2×	0.003	IFNL4
cellular response to gonadotropin stimulus	1	702.2×	0.003	PAX8
otic vesicle development	1	702.2×	0.003	PAX8
positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis	1	702.2×	0.003	PAX8
defense response to virus	2	34.7×	0.003	IFNL3, IFNL4
pronephros development	1	601.9×	0.003	PAX8
mesenchymal to epithelial transition involved in metanephros morphogenesis	1	526.6×	0.004	PAX8
mesonephros development	1	383.0×	0.005	PAX8
urogenital system development	1	247.8×	0.007	PAX8
positive regulation of branching involved in ureteric bud morphogenesis	1	200.6×	0.009	PAX8

Therapeutics

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 3

Druggability breadth: 1 of 4 evidence-associated genes (25%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
PAX8	SORAFENIB TOSYLATE

Top cohort targets by molecule count

Symbol	Molecules	Max phase
PAX8	14	4
IFNL3	0	0
IFNL4	0	0
HOXD3	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
SORAFENIB TOSYLATE	4	PAX8
MITOXANTRONE HYDROCHLORIDE	4	PAX8
TEGASEROD MALEATE	4	PAX8
DAUNORUBICIN HYDROCHLORIDE	4	PAX8
DIGOXIN	4	PAX8
DOXORUBICIN HYDROCHLORIDE	4	PAX8
HEXACHLOROPHENE	4	PAX8
THIOGUANINE	4	PAX8
CHLORHEXIDINE	4	PAX8
VORINOSTAT	4	PAX8
ENPIROLINE	2	PAX8
PINAFIDE	2	PAX8
LANATOSIDE C	2	PAX8
IODOQUINOL	2	PAX8

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
PAX8	3	Functional:3

Pharmacogenomics

Cohort genes with a PharmGKB record: 4; with CPIC/DPWG dosing guidelines: 1.

Cohort genes with a CPIC/DPWG dosing guideline

Symbol	CPIC guidelines
IFNL3	1

Chemical tractability of cohort targets

14 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
SORAFENIB TOSYLATE	4	PAX8
MITOXANTRONE HYDROCHLORIDE	4	PAX8
TEGASEROD MALEATE	4	PAX8
DAUNORUBICIN HYDROCHLORIDE	4	PAX8
DIGOXIN	4	PAX8
DOXORUBICIN HYDROCHLORIDE	4	PAX8
HEXACHLOROPHENE	4	PAX8
THIOGUANINE	4	PAX8
CHLORHEXIDINE	4	PAX8
VORINOSTAT	4	PAX8
ENPIROLINE	2	PAX8
PINAFIDE	2	PAX8
LANATOSIDE C	2	PAX8
IODOQUINOL	2	PAX8

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	PAX8
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	3	IFNL3, IFNL4, HOXD3

Undrugged target profiles

3 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
IFNL3	0	—
IFNL4	0	—
HOXD3	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 22.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	8
PHASE3	5
PHASE1	5
EARLY_PHASE1	2
PHASE1/PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01167712	PHASE3	ACTIVE_NOT_RECRUITING	Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
NCT00108745	PHASE3	UNKNOWN	Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer
NCT00262847	PHASE3	COMPLETED	Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT00719303	PHASE3	UNKNOWN	Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT00951496	PHASE3	COMPLETED	Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT02068794	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer
NCT02834013	PHASE2	ACTIVE_NOT_RECRUITING	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
NCT04739800	PHASE2	ACTIVE_NOT_RECRUITING	Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
NCT05500391	PHASE2	RECRUITING	Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring
NCT00888615	PHASE2	COMPLETED	Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT01097746	PHASE2	COMPLETED	First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
NCT02364713	PHASE2	TERMINATED	MV-NIS or Investigator’s Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer
NCT02853318	PHASE2	COMPLETED	Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02923739	PHASE2	TERMINATED	Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT04092270	PHASE1	ACTIVE_NOT_RECRUITING	A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer
NCT00989651	PHASE1	COMPLETED	Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
NCT01074411	PHASE1	COMPLETED	Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT02020707	PHASE1	COMPLETED	Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers
NCT05498597	PHASE1	UNKNOWN	AMT-151 in Patients With Selected Advanced Solid Tumours
NCT05415709	EARLY_PHASE1	RECRUITING	Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer
NCT01504126	EARLY_PHASE1	COMPLETED	Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT03641287	Not specified	TERMINATED	The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PACLITAXEL	4	11
BEVACIZUMAB	4	1
TOPOTECAN HYDROCHLORIDE	4	1
VELIPARIB	3	2
CEDIRANIB MALEATE	3	1
ELESCLOMOL	3	1
EMACTUZUMAB	3	1
PACLITAXEL POLIGLUMEX	3	1
NEDISERTIB	1	1
S-ROLIPRAM	0	1